title: Endocrinological disturbances in chronic obstructive pulmonary disease.
abstract: In this overview, the available literature on endocrinological disturbances in chronic obstructive pulmonary disease (COPD) is reviewed, with stress on growth hormone/insulin-like growth factor I (IGF-I), thyroid hormone and the anabolic steroids. In COPD, little is known about circulating growth hormone or IGF-I concentrations. Some authors find a decrease in growth hormone or IGF-I, others an increase. An increase of growth hormone might reflect a nonspecific response of the body to stress (for instance, hypoxaemia). Until now, only one controlled study on growth hormone supplementation has been published, which however did not reveal any functional benefits. Before growth hormone supplementation can be advised as part of the treatment in COPD, further controlled studies must be performed to investigate its functional efficacy. The prevalence of thyroid dysfunction in COPD and its role in pulmonary cachexia has not been extensively studied. So far, there is no evidence that thyroid function is consistently altered in COPD, except perhaps in a subgroup of patients with severe hypoxaemia. Further research is required to more extensively study the underlying mechanisms and consequences of disturbed thyroid function in this subgroup of COPD patients. A few studies have reported the results of anabolic steroid supplementation in chronic obstructive pulmonary disease. Although some studies have discerned that low circulating levels of testosterone are common in males with chronic obstructive pulmonary disease, little is known about the prevalence, the underlying causes or functional consequences of hypogonadism in these patients. The use of systemic glucocorticosteroids and an influence of the systemic inflammatory response have been suggested as contributing to low testosterone levels. It can be hypothesised that low anabolic hormones will reduce muscle mass and eventually result in a diminished muscle function. Further evidence is required before testosterone replacement can be recommended for males with chronic obstructive pulmonary disease.
authors: Dept of Respiratory Medicine, University Hospital Maastricht, The Netherlands. E.Creutzberg@PUL.Unimaas.NL
authors: E C
authors: EC
authors: Creutzberg
authors: R
authors: R
authors: Casaburi
mesh_terms: D045930:Anabolic Agents / Q000627:therapeutic use; D000818:Animals; D013006:Growth Hormone / Q000378:metabolism / Q000627:therapeutic use; D020249:Hormone Replacement Therapy; D006728:Hormones / Q000378:metabolism* / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D029424:Pulmonary Disease, Chronic Obstructive / Q000378:metabolism*; D013739:Testosterone / Q000378:metabolism / Q000627:therapeutic use; D013963:Thyroid Hormones / Q000378:metabolism
chemical_list: D045930:Anabolic Agents; D006728:Hormones; D013963:Thyroid Hormones; D013739:Testosterone; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone